Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To document the effects of appropriate and inappropriate empirical antibiotic therapy on mortality in a cohort of patients with bacteraemia due to methicillin-resistant Staphylococcus aureus (MRSA) and to summarize effects with previous studies. METHODS: In the retrospective cohort study, episodes of clinically significant MRSA bacteraemia during a 15 year period were included. Polymicrobial episodes were excluded unless MRSA was isolated in more than one bottle and co-pathogens were given appropriate empirical antibiotic treatment. Appropriate empirical treatment was defined as matching in vitro susceptibility and started within 48 h of blood-culture taking, except for single aminoglycosides or rifampicin. We assessed univariate and multivariate associations between appropriate empirical therapy and 30 day all-cause mortality. Multivariable analysis was conducted using backward stepwise logistic regression. We reviewed all studies assessing the effects of appropriate empirical antibiotic treatment on mortality for MRSA infections and compiled adjusted odds ratios (ORs) using a random effects meta-analysis. RESULTS: Five hundred and ten episodes of MRSA bacteraemia were included. There were no cases of community-acquired infection. The 30 day mortality was 43.9% (224/510) and was stable throughout the study period. Mortality was significantly higher among patients receiving inappropriate (168/342, 49.1%) compared with those receiving appropriate (56/168, 33.3%) empirical antibiotic treatment, P = 0.001. In the adjusted analysis the OR was 2.15 [95% confidence interval (CI) 1.34-3.46]. Pooling of six studies using adequate methodology for the adjusted analysis resulted in an OR of 1.98 (95% CI 1.62-2.44). CONCLUSIONS: Appropriate empirical antibiotic treatment has a significant survival benefit in MRSA bacteraemia. Treatment guidelines should consider this benefit.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among patients with documented MRSA infections, delays of > 24–48 h until antibiotic administration are associated with increased mortality in some studies [143–147], but not in others [148–154].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [146]
Citations
Cites
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767
(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Chang, F.-Y., Peacock, J. E., Musher, D. M., Triplett, P., MacDonald, B. B., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091184.93122.09 · Cited by 530
Stryjewski, M. E., Szczech, L. A., Benjamin, D. K., Inrig, J. K., Kanafani, Z. A., Engemann, J. J., Chu, V. H., Joyce, M. J., Reller, L. B., Corey, G. R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510386 · Cited by 348
Kim, S.-H., Kim, K.-H., Kim, H.-B., Kim, N.-J., Kim, E.-C., Oh, M.-D., & Choe, K.-W. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00700-07 · Cited by 300
Pathogenic Significance of Methicillin Resistance for Patients with Staphylococcus aureus Bacteremia
Soriano, A., Martinez, J. A., Mensa, J., Marco, F., Almela, M., Moreno-Martinez, A., Sanchez, F., Munoz, I., Jimenez de Anta, M. T., & Soriano, E. (2000) · Clinical Infectious Diseases · doi:10.1086/313650 · Cited by 256
Paul, M., Andreassen, S., Tacconelli, E., Nielsen, A. D., Almanasreh, N., Frank, U., Cauda, R., & Leibovici, L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl372 · Cited by 214
Self-citationLodise, T. P., & McKinnon, P. S. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.02.007 · Cited by 199
Research works printed but not linked: 1
- EARSS, 2009, European Antimicrobial Resistance Surveillance System
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
The Role of Macrophages in Staphylococcus aureus Infection
Pidwill, G. R., Gibson, J. F., Cole, J., Renshaw, S. A., & Foster, S. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620339 · Cited by 341
Kadri, S. S., Lai, Y. L., Warner, S., Strich, J. R., Babiker, A., Ricotta, E. E., Demirkale, C. Y., Dekker, J. P., Palmore, T. N., Rhee, C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30477-1 · Cited by 279
Rottier, W. C., Ammerlaan, H. S. M., & Bonten, M. J. M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks065 · Cited by 225
Marquet, K., Liesenborgs, A., Bergs, J., Vleugels, A., & Claes, N. (2015) · Critical Care · doi:10.1186/s13054-015-0795-y · Cited by 203
“After quality assessment of the individual studies, 27 studies [8,12,19,21,22,33,34, 36-48,50-52,54-57] were included in the systematic review.”
BackgroundMethodInfluentialCombination therapy for carbapenem-resistant Gram-negative bacteria
Paul, M., Carmeli, Y., Durante-Mangoni, E., Mouton, J. W., Tacconelli, E., Theuretzbacher, U., Mussini, C., & Leibovici, L. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku168 · Cited by 210
Self-citationMorata, L., Cobos-Trigueros, N., Martínez, J. A., Soriano, Á., Almela, M., Marco, F., Sterzik, H., Núñez, R., Hernández, C., & Mensa, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00750-12 · Cited by 163
“Other observations have also supported the importance of appropriate empirical therapy in patients with bacteremia in general (26) or due to particular pathogens, such as methicillin-resistant Staphylococcus aureus (22) or Escherichia coli (21).”
ResultAppropriate antimicrobial therapy in the era of multidrug-resistant human pathogens
Pogue, J. M., Kaye, K. S., Cohen, D. A., & Marchaim, D. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.025 · Cited by 156
Staphylococcus aureusbacteraemia and endocarditis – epidemiology and outcome: a review
Ásgeirsson, H., Thalme, A., & Weiland, O. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1392039 · Cited by 163
Following the Mechanisms of Bacteriostatic versus Bactericidal Action Using Raman Spectroscopy
Bernatová, S., Samek, O., Pilát, Z., Šerý, M., Ježek, J., Jákl, P., Šiler, M., Krzyžánek, V., Zemánek, P., Holá, V., et al. (2013) · Molecules · doi:10.3390/molecules181113188 · Cited by 155
Bassetti, M., Rello, J., Blasi, F., Goossens, H., Sotgiu, G., Tavoschi, L., Zasowski, E. J., Arber, M. R., McCool, R., Patterson, J. V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106184 · Cited by 123
Bassetti, M., Trecarichi, E. M., Mesini, A., Spanu, T., Giacobbe, D. R., Rossi, M., Schenone, E., PASCALE, G. D., Molinari, M. P., Cauda, R., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03679.x · Cited by 127
“We did not detect vancomycin hetero-resistance, in agreement with a recent study from a UK hospital [27].”
ResultChong, Y. P., Park, S., Kim, H. S., Kim, E. S., Kim, M., Park, K., Kim, S., Lee, S., Choi, S., Jeong, J., et al. (2013) · Medicine · doi:10.1097/md.0b013e318289ff1e · Cited by 125
Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections
van Hal, S. J., Tong, S. Y. C., & Davis, J. S. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1396906 · Cited by 118
Clinical Impact of a Real-Time PCR Assay for Rapid Identification of Staphylococcal Bacteremia
Frye, A. M., Baker, C. A., Rustvold, D. L., Heath, K., Hunt, J., Leggett, J. E., & Oethinger, M. D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.06169-11 · Cited by 102
“Specifically, a delay in appropriate antibiotic treatment greater than 44 to 48 h after the collection of a blood culture positive for MRSA is associated with increased infection-related mortality and a prolonged length of hospital stay (11, 13).”
BackgroundPredicting Risk for Death from MRSA Bacteremia1
Pastagia, M., Kleinman, L. C., Lacerda de la Cruz, E. G., & Jenkins, S. G. (2012) · Emerging Infectious Diseases · doi:10.3201/eid1807.101371 · Cited by 95
“found a signifi cant increase in 30-day mortality rates for patients given incorrect therapy within 48 hours of blood culture (32).”
BackgroundThe Japanese guidelines for the management of sepsis
Oda, S., Aibiki, M., Ikeda, T., Imaizumi, H., Endo, S., Ochiai, R., Kotani, J., Shime, N., Nishida, O., Noguchi, T., et al. (2014) · Journal of Intensive Care · doi:10.1186/s40560-014-0055-2 · Cited by 95
“A study in patients with MRSA bloodstream infection also showed a similar trend [56].”
ResultCycling Empirical Antibiotic Therapy in Hospitals: Meta-Analysis and Models
Wiesch, P. A. Z., Kouyos, R. D., Abel, S., Viechtbauer, W., & Bonhoeffer, S. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004225 · Cited by 94
“being assigned to an ineffective initial treatment [13,14].”
BackgroundThe Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia
McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit560 · Cited by 90
Gasch, O., Camoez, M., Dominguez, M. A., Padilla, B., Pintado, V., Almirante, B., Molina, J., Lopez-Medrano, F., Ruiz, E., Martinez, J. A., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12108 · Cited by 86
Thrombocytopenia in Staphylococcus aureus Bacteremia: Risk Factors and Prognostic Importance
Gafter‐Gvili, A., Mansur, N., Bivas, A., Zemer‐Wassercug, N., Bishara, J., Leibovici, L., & Paul, M. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0705 · Cited by 94
Self-citationClinical implications of β-lactam–aminoglycoside synergism: systematic review of randomised trials
Marcus, R., Paul, M., Elphick, H., & Leibovici, L. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.029 · Cited by 84
Self-citationCharacteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality
Bassetti, M., Peghin, M., Trecarichi, E. M., Carnelutti, A., Righi, E., Giacomo, P. D., Ansaldi, F., Trucchi, C., Alicino, C., Cauda, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170236 · Cited by 86
Li, Z., Zhuang, H., Wang, G., Wang, H., & Dong, Y. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05763-y · Cited by 82
Cressman, A. M., MacFadden, D. R., Verma, A. A., Razak, F. A., & Daneman, N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1031 · Cited by 83
“This is in keeping with an association of inadequate treatment with mortality, with this relationship being strongest among patients presenting with higher severity of illness [10, 14].”
BackgroundMüller, S., Wolf, A. J., Iliev, I. D., Berg, B. L., Underhill, D. M., & Liu, G. Y. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.10.011 · Cited by 72
“Based on reports, between 30–80% of individuals infected with MRSA were inappropriately treated, often with β-lactam antibiotics (Paul et al., 2010, Kim et al., 2004, Rodriguez-Bano et al., 2009).”
BackgroundLueangarun, S., & Leelarasamee, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/765205 · Cited by 62
“demonstrated that inappropriate antimicrobials in MRSA septicemia obviously increased a risk for mortality [52].”
BackgroundArdebili, A., Izanloo, A., & Rastegar, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2184346 · Cited by 72
“Indeed, inappropriate initial empirical therapy serves as a likely confounder [159], as the comparative time to covering antibiotic treatment is longer in patients treated with colistin monotherapy than patients with combination regimen; the latter is more likely to cover earlier empirical antibiotic therapy in patien…”
BackgroundShang, W., Rao, Y., Zheng, Y., Yang, Y., Hu, Q., Hu, Z., Yuan, J., Peng, H., Xiong, K., Tan, L., et al. (2019) · mBio · doi:10.1128/mbio.00880-19 · Cited by 70
“Owing to failure to initially recognize MRSA infection, between 30% and 80% of individuals infected with MRSA have been reported to be inappropriately treated with -lactam antibiotics (7, 8).”
BackgroundGudiol, F., Aguado, J. M., Almirante, B., Bouza, E., Cercenado, E., Domínguez, M. Á., Gasch, O., Lora-Tamayo, J., Miró, J. M., Palomar, M., et al. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.015 · Cited by 78
“63,69,70 Finally, some authors conclude that the appropriateness of the empirical treatment may only have impact in particular subpopulations, namely those with severe or complicated SAB, 68 non-removable source of SAB, 71 or patients with less severe SAB.”
Edwards, B., Milne, K., Lawes, T., Cook, I., Robb, A., & Gould, I. M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05520-11 · Cited by 70
“Methicillin-resistant Staphylococcus aureus (MRSA) is an important community and hospital pathogen which, when isolated from blood, carries a high mortality rate despite appropriate first-line antimicrobial therapy (4, 24).”
BackgroundRaman spectroscopic identification of single bacterial cells under antibiotic influence
Münchberg, U., Rösch, P., Bauer, M. W., & Popp, J. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7747-2 · Cited by 67
Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?
Kamath, S., Altaq, H. H., & Abdo, T. (2023) · Microorganisms · doi:10.3390/microorganisms11092231 · Cited by 69
“Observational data show that earlier MRSA coverage led to better outcomes in patients with known MRSA infection but may be associated with increased adverse events and mortality in MRSA-negative patients [123–126].”
Corl, K. A., Zeba, F., Caffrey, A. R., Hermenau, M., Lopes, V., Phillips, G. S., Merchant, R. C., Levy, M. M., & LaPlante, K. L. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004212 · Cited by 62
Horino, T., Sato, F., Hosaka, Y., Hoshina, T., Tamura, K., Nakaharai, K., Kato, T., Nakazawa, Y., Yoshida, M., & Hori, S. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000350 · Cited by 59
Felsenstein, S., Bender, J. M., Sposto, R., Gentry, M., Takemoto, C., & Bard, J. D. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0119-oa · Cited by 56
Decision-support models for empiric antibiotic selection in Gram-negative bloodstream infections
MacFadden, D. R., Coburn, B. A., Shah, N. S., Robicsek, A. A., Savage, R., Elligsen, M., & Daneman, N. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.029 · Cited by 58
Gasch, O., Camoez, M., Dominguez, M. A., Padilla, B., Pintado, V., Almirante, B., Lepe, J. A., Lagarde, M., Ruiz de Gopegui, E., Martinez, J. A., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt016 · Cited by 52
Wong, D., Wong, T., Romney, M. G., & Leung, V. C. M. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0143-3 · Cited by 51
“aureus (MRSA) at some centres [3–8].”
Ciapponi, A., Bardach, A., Sandoval, M. M., Palermo, M., Navarro, E., Espinal, C., & Quiros, R. E. (2023) · Emerging infectious diseases · doi:10.3201/eid2911.230753 · Cited by 55
“Of note, several studies have identified the asso - ciation of inappropriate empirical antibiotic treat-ment with increased lethality among patients with MRSA bacteremia ( 39 , 40 ).”
BackgroundOlajuyigbe, O. O., Tolulope, I., & Roger, C. (2017) · African Health Sciences · doi:10.4314/ahs.v17i3.23 · Cited by 57
Nanotheranostic approaches for management of bloodstream bacterial infections
Jagtap, P., Sritharan, V., & Gupta, S. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.09.005 · Cited by 48
Jokinen, E., Laine, J., Huttunen, R., Rahikka, P., Huhtala, H., Vuento, R., Vuopio, J., & Syrjänen, J. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1292046 · Cited by 49
“death in MRSA bacteremia [17,32,33] However, Kaash”
Predictive Utility of Prior Positive Urine Cultures
MacFadden, D. R., Ridgway, J. P., Robicsek, A. A., Elligsen, M., & Daneman, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu588 · Cited by 44
Кirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 63
“treatment has been associated with lower mortality in patients with MRSAB [11,130].”
BackgroundCarretto, E., Bardaro, M., Russello, G., Mirra, M., Zuelli, C., & Barbarini, D. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02103-12 · Cited by 39
“Different studies demonstrate that delayed appropriate therapy in SA-BSIs is related to an increase in the mortality rate, as well as prolonging hospital stays and increasing costs (4, 5).”
BackgroundFalcone, M., Russo, A., & Venditti, M. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.012 · Cited by 41
“Daptomycin plus ceftaroline was used in 26 cases of persisting staphylococcal bacteremia (20 MRSA, 2 VISA, 2 MSSA, 2 methicillin-resistant S epidermidis); after daptomycin plus ceftaroline was started, the median time to bacteremia clearance was 2 days (range, 1e6 days) with recovery of patients, and in vitro studies…”
BackgroundInfluentialYoon, Y. K., Park, D. W., Sohn, J. W., Kim, H. Y., Kim, Y.-S., Lee, C.-S., Lee, M. S., Ryu, S.-Y., Jang, H.-C., Choi, Y. J., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1650-8 · Cited by 34
“[21] speculated that the studies did not confirm an advantage to empirical vancomycin treatment, as the prevalence of vancomycin MICs >1.”
BackgroundThe preSABATO study group*, Kaasch, A. J., Rieg, S., Kuetscher, J., Brodt, H. R., Widmann, T., Herrmann, M., Meyer, C., Welte, T., Kern, P., et al. (2013) · Infection · doi:10.1007/s15010-013-0428-9 · Cited by 42
Risk factors for long-term mortality of Staphylococcus aureus bacteremia
Yahav, D., Yassin, S., Shaked, H., Goldberg, E., Bishara, J., Paul, M., & Leibovici, L. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2598-8 · Cited by 35
Self-citationSurvival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants
Thaden, J. T., Ericson, J. E., Cross, H., Bergin, S. P., Messina, J. A., Fowler, V. G., Benjamin, D. K., Clark, R. H., Hornik, C. P. V., & Smith, P. B. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000850 · Cited by 36
“44 African-American 182 (26) 673 (27) Hispanic 154 (22) 487 (19) Other 36 (5) 131 (5) 5-min Apgar 0–3 34 (5) 123 (5) 0.”
Cuny, C., Layer, F., Werner, G., Harmsen, D., Daniels-Haardt, I., Jurke, A., Mellmann, A., Witte, W., & Köck, R. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.02.013 · Cited by 38
Papakonstantinou, P. Ε., Samonis, G., Andrianaki, A. M., Christofaki, M., Dimopoulou, D., Papadakis, J. A., Gikas, A. I., & Kofteridis, D. P. (2018) · Infection and Chemotherapy · doi:10.3947/ic.2018.50.1.21 · Cited by 35
“The initial empirical antimicrobial therapy was considered appropriate if the causative pathogen was susceptible to the agent used [17].”
MethodHolmes, N. E., Robinson, J. O., van Hal, S. J., Munckhof, W., Athan, E., Korman, T. M., Cheng, A. C., Turnidge, J. D., Johnson, P. D. R., & Howden, B. P. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3011-2 · Cited by 37
“Appropriate empiric therapy was also associated with lower treatment failure, consistent with the literature that delays in appropriate therapy are associated with inferior outcomes [54, 55], although confounding by indication has also been observed when evaluating appropriate antibiotic therapy [56].”
ResultSimor, A. E., Pelude, L., Golding, G. R., Fernandes, R., Bryce, E., Frenette, C. H., Gravel, D., Katz, K. C., McGeer, A., Mulvey, M. R., et al. (2016) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2015.323 · Cited by 34
Ortwine, J. K., & Bhavan, K. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1435128 · Cited by 38
“choice of antibacterial therapy affect MRSA bacteremia outcomes [10], and current treatments for bacteremia are less”
BackgroundMacFadden, D. R., Coburn, B. A., Shah, N., Robicsek, A. A., Savage, R., Elligsen, M., & Daneman, N. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.07.032 · Cited by 33
“When particular antibiotics were not routinely tested as part of standard practice we assigned them to be susceptible or resistant in the following scenarios where intrinsic susceptibility or resistance is known to be universal or near universal: (1) Pseudomonas aeruginosa assumed to be intrinsically resistant to ceft…”
BackgroundBello‐Chavolla, O. Y., Bahena-López, J. P., Garciadiego-Fossas, P., Volkow, P., Garcia‐Horton, A., Velázquez-Acosta, C., & Vilar‐Compte, D. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4275-1 · Cited by 31
Wang, A., Daneman, N., Tan, C., Brownstein, J. S., & MacFadden, D. R. (2017) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.222 · Cited by 31
Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia
Bishara, J., Goldberg, E., Leibovici, L., Samra, Z., Shaked, H., Mansur, N., & Paul, M. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.02.009 · Cited by 36
Self-citationJacobs, D. M., & Shaver, A. L. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.11.014 · Cited by 33
Hung, Y.-P., Lee, C.-C., & Ko, W.-C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869822 · Cited by 29
Emergency medicine updates: Management of sepsis and septic shock
Long, B., & Gottlieb, M. A. (2025) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2025.01.054 · Cited by 34
Komoto, A., Maiguma, T., Teshima, D., Sugiyama, T., & Haruki, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203453 · Cited by 29
Salimnia, H., Fairfax, M. R., Lephart, P., Morgan, M. A., Gilbreath, J. J., Butler‐Wu, S. M., Templeton, K. E., Hamilton, F., Wu, F., Buckner, R. J., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-14 · Cited by 26
Guillamet, C. V., Guillamet, R. V., Deaton, B., Shroba, J., Vazquez, L., & Mercier, R.-C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01902-17 · Cited by 26
“9 years in our group versus older than 70 years in other cohorts) and fewer comorbidities could explain the lower short-term mortality rate in our cohort (7, 9).”
Understanding why resistant bacteria are associated with higher mortality in ICU patients
Barbier, F., Lisboa, T. C., & Nseir, S. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-4138-x · Cited by 26
“Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections are similarly exposed to high rates of IIAT, resulting in a twofold rise in the adjusted probability of death [10].”
BackgroundCoulter, S., Roberts, J. A., Hajkowicz, K. M., & Halton, K. A. (2017) · Infectious Disease Reports · doi:10.4081/idr.2017.6849 · Cited by 26
Picot-Guéraud, R., Batailler, P., Caspar, Y., Hennebique, A., & Mallaret, M. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2015.05.004 · Cited by 25
Kim, T., Chong, Y. P., Park, K., Bang, K. M., Park, S., Kim, S., Jeong, J., Lee, S., Choi, S., Woo, J. H., et al. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.351 · Cited by 25
“Despite the availability of appropriate therapies, the 30-day mortality rate of patients with MRSA bloodstream infections remains at 30% to 40% [3,4].”
BackgroundRapid Microbial Sample Preparation from Blood Using a Novel Concentration Device
Boardman, A. K., Campbell, J., Wirz, H., Sharon, A., & Sauer-Budge, A. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116837 · Cited by 28
“Although this approach is effective, it is too slow and can lead to delayed and inappropriate treatment that can result in increased antibiotic resistance, longer lengths of stay in the hospital, and increased morbidity and mortality [4,5,6,7,8,9,10].”
Luo, Y., Guo, Z., Li, Y., Ouyang, H., Huang, S., Chen, Y., Li, K., Ji, Y., Zhu, H., Luo, W., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s402172 · Cited by 23
Yossepowitch, O., Dan, M., Kutchinsky, A., Gottesman, T., & Schwartz–Harari, O. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.01.001 · Cited by 23
“Any delay in appropriate antibiotic treatment, even a delay of no more than 48 hours, is an independent predictor of longer hospital stay, infection-related mortality, and secondary infectious complications (such as endocarditis and vertebral osteomyelitis) (Lodise et al., 2003; Paul et al., 2010).”
BackgroundBlomfeldt, A., Eskesen, A. N., Aamot, H. V., Leegaard, T. M., & Bjørnholt, J. V. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2601-4 · Cited by 23
“aureus (MRSA) is an independent risk factor for mortality [6, 7]; hence, knowledge of the local prevalence is crucial when choosing empirical antibiotic treatment [8].”
Towards a Definition for Health Care–Associated Infection
Friedman, N. D., Levit, D., Taleb, E., Marcus, G., Michaeli, L., Broide, M., Mengesha, B., Zaidenstein, R., Lazarovitch, T., Dadon, M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy116 · Cited by 23
“Delay in the administration of appropriate antimicrobials is the strongest modifiable and independent predictor for mortality in severe sepsis [14].”
BackgroundKang, C., Sung, Y. K., Lee, K. H., Lee, K. T., & Lee, J. K. (2012) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2012.730151 · Cited by 23
Delport, J. A., Mohorovic, I., Burn, S., McCormick, J. K., Schaus, D., Lannigan, R., & John, M. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000285 · Cited by 23
Cardoso, T., Ribeiro, O., Aragão, I. C., Costa‐Pereira, A., & Sarmento, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058418 · Cited by 22
“There are several studies describing the negative impact of initial inadequate antibiotic therapy on mortality [25–32].”
BackgroundBal, A. M., Garau, J., Gould, I. M., Liao, C., Mazzei, T., Nimmo, G. R., Soriano, À., Stefani, S., & Tenover, F. C. (2013) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2013.01.002 · Cited by 23
“MRSA infections often still result in poor outcomes [4].”
BackgroundArakawa, S., Kasai, M., Kawai, S., Sakata, H., & Mayumi, T. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.11.011 · Cited by 26
Lee, H.-Y., Chen, C., Liu, S., Yan, Y.-S., Chang, C., & Chiu, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136171 · Cited by 23
“This was also described in previous studies that identified delay in the initiation of appropriate antimicrobial therapy as an integral determinant of poor clinical outcomes for severe diseases, such as MRSA bacteremia [12,13].”
MethodResultAratani, T., Tsukamoto, H., Higashi, T., Kodawara, T., Yano, R., Hida, Y., Iwasaki, H., & Goto, N. (2021) · Journal of International Medical Research · doi:10.1177/03000605211058872 · Cited by 23
“In previous studies, initiation of appropriate antimicrobial treatment varied from 24 to 72 hours after blood culture collection.(4,11,13,14) In other studies, the time to initiation of appropriate antibiotic treatment was defined either as the time since a positive blood culture was reported or the time after bactere…”
ResultDryden, M., Andrašević, A. T., Bassetti, M., Bouza, E., Chastre, J. E., Baguneid, M. S., Esposito, S., Giamarellou, H., Gyssens, I. C., Nathwani, D., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(15)30002-9 · Cited by 20
“Inappropriate empirical antibiotic therapy in patients with MRSA bacteraemia is associated with a significant increase in mortality, prolonged length of stay (LOS) and increased hospital costs [95].”
BackgroundWi, Y. M., Rhee, J.-Y., Kang, C., Chung, D. R., Song, J., & Peck, K. R. (2018) · Epidemiology and Infection · doi:10.1017/s0950268818001255 · Cited by 22
“In addition, Pitt Bacteraemia Scores were determined for all patients [19].”
BackgroundMatsumoto, K., Kanazawa, N., Watanabe, E. M., Yokoyama, Y., Fukamizu, T., Shimodozono, Y., Maeda, C., Yasuda, T., Kakihana, Y., Ikawa, K., et al. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00911 · Cited by 20
MacFadden, D. R., Elligsen, M., Robicsek, A. A., Ricciuto, D. R., & Daneman, N. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130364 · Cited by 19
Κατσαρού, Ι., Paraskevopoulou, N.-M., Papadimitriou‐Olivgeris, M., Giormezis, N., Militsopoulou, M., Kolonitsiou, F., Marangos, M. N., Anastassiou, E. D., & Spiliopoulou, I. T. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03742-5 · Cited by 19
“The timely administration of appropriate antimicrobial therapy is a well described predictor of survival among staphylococcal infections [9, 11, 19].”
BackgroundGómez-Mejía, A., Arnold, K., Bär, J., Singh, K. D., Scheier, T., Brugger, S. D., Zinkernagel, A. S., & Sinues, P. (2022) · iScience · doi:10.1016/j.isci.2022.105080 · Cited by 19
“A prompt and accurate identification of the causative pathogens of a bacterial infection is essen57 tial for providing patients with adequate treatments to reduce mortality and to prevent antibiotic 58 resistance (1-4).”
BackgroundWong, D., Wong, T., Romney, M. G., & Leung, V. C. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1564-5 · Cited by 19
“aureus (MRSA) as up to 50–60 % of bloodstream isolates are methicillin-resistant at some centres [3–8].”
BackgroundJu, M., Huang, Y., Xu, X., Qian, Y., Bi, Y., Liu, S., Dong, S., Yuan, J., & Lin, D. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-932 · Cited by 18
Carey, G. B., Holleck, J. L., Alshaeba, S. E., Jayakrishnan, R., Gordon, K. S., Grimshaw, A. A., & Gunderson, C. G. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad078 · Cited by 18
Economic burden of antimicrobial resistance and inappropriate empiric treatment in Thailand
Kongnakorn, T., Tichy, E., Kengkla, K., Kanokwanvimol, N., Suthipinijtham, P., Phuripakathorn, C., & Al-Taie, A. (2023) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2023.169 · Cited by 18
“Loss due to premature death 360,685 (11,617) 432,043 (13,916) 643,524 (20,727) 537,135 (17,300) 432,432 (13,928)”
Robinson, J. O., Phillips, M. R., Christiansen, K., Pearson, J. C., Coombs, G. W., & Murray, R. J. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12388 · Cited by 19
“of antibiotics without in vitro activity against MRSA while susceptibility results are pending; inappropriate therapy given within the first 45–8 h after the blood culture was taken has been shown to be an independent predictor of mortality in MRSA bacteraemia [5,6].”
BackgroundJoo, E.-J., Peck, K. R., Ha, Y. E., Kim, Y.-S., Song, Y. G., Lee, S.-S., Ryu, S.-Y., Moon, C., Lee, J. H., & Park, K.-H. (2013) · Journal of Hospital Infection · doi:10.1016/j.jhin.2012.12.008 · Cited by 20
“Appropriateness of empiric therapy should be addressed in the analysis of risk factors for poor outcomes in MRSA bacteraemia.(22,23) In this study, however, we have collected patients’ data during periods between initiation and completion of the appropriate therapy for MRSA bacteraemia.”
BackgroundAlosaimy, S., Lagnf, A. M., Hobbs, A. L. V., Mubarez, M., Kufel, W. D., Morrisette, T., Polisetty, R. S., Li, D., Veve, M. P., Simon, S. P., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac670 · Cited by 19
Joo, E., Chung, D. R., Ys, K., Baek, J. Y., Lee, N. Y., Cho, S. Y., Ha, Y. E., Kang, C., Peck, K. R., & Song, J. (2017) · Infection and Chemotherapy · doi:10.3947/ic.2017.49.2.109 · Cited by 20
“aureus bacteremia, delayed treatment was found to be an independent predictor of infection-related mortality [20, 21], and a meta-analysis of MRSA bacteremia showed that appropriate empirical antibiotic treatment had a significant survival benefit [21].”
ResultMacFadden, D. R., Melano, R. G., Coburn, B. A., Tijet, N., Hanage, W. P., & Daneman, N. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01780-18 · Cited by 18
“Infections due to antibiotic-resistant organisms are associated with increased morbidity and mortality, and this may be due in part to inadequate initial empirical antibiotic therapy (3, 4).”
Background
Metadata
- Authors
- Paul, M., Kariv, G., Goldberg, E., Raskin, M., Shaked, H., Hazzan, R., Samra, Z., Paghis, D., Bishara, J., & Leibovici, L.
- Affiliations
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
- Corresponding author
- Paul, Mical
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-14
- Volume
- 65
- Issue
- 12
- Pages
- 2658-2665
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2112191002
- Cited by
- 224
- References
- 44
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 1 · 2023: 12 · 2022: 13 · 2021: 20 · 2020: 11 · 2019: 12 · 2018: 18 · 2017: 21 · 2016: 18 · 2015: 20 · 2014: 19 · 2013: 22 · 2012: 14
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- methicillin-resistant Staphylococcus aureus, MRSA bacteremia, empirical antibiotic therapy, 30-day mortality, antimicrobial susceptibility, community-acquired MRSA, treatment guidelines
- MeSH terms
- Aged, Aged, 80 and over, Anti-Bacterial Agents, Blood, Cross Infection, Culture Media, Female, Humans, Male, Medication Errors, Microbial Sensitivity Tests, Middle Aged, Risk Factors, Staphylococcal Infections, Cohort Studies, Multivariate Analysis, Odds Ratio, Bacteremia, Treatment Outcome, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.